Clinical trial Recruiting at 1 site Observational Ages 18 and up

TIMELY-PrädiktoR: predicting who benefits from cardiac rehabilitation

Official title: TIMELY-PrädiktoR Prospective Study

Run by University of Witten/Herdecke · NCT05461729 · Data updated 2026-11-12

The project will collect detailed health, lifestyle, and rehab data from people with coronary artery disease in phase II cardiac rehabilitation to see if AI can find patterns that predict who benefits most.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1200 (estimated)
SponsorUniversity of Witten/Herdecke
Academic / other
Locations1 site (Ennepetal, North Rhine-Westphalia)
StatusRecruiting
StartedJune 1, 2021
Main results expectedAugust 31, 2029
Study endsAugust 31, 2029
Registry record updatedMarch 30, 2026
Trial IDNCT05461729 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with coronary artery disease after myocardial infarction, angioplasty/PCI, or coronary artery bypass who are enrolled in and able to participate in phase II cardiac rehabilitation and can provide informed consent.

Probably not a fit

Patients with unstable coronary or cerebrovascular conditions, acute infections, or those unable to participate in phase II cardiac rehabilitation or to give informed consent are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

TIMELY-PrädiktoR is an observational program that gathers high-resolution clinical, behavioral, and remote-monitoring data from coronary artery disease patients participating in phase II cardiac rehabilitation. The protocol records biological, psychological, and social variables alongside telemedicine and lifestyle measures to build a comprehensive dataset. Machine-learning and data-mining methods will be applied to identify intra-individual factors and interactions linked to rehabilitation success and future risk. Participants receive standard cardiac rehabilitation while data are collected at Klinik Königsfeld for analysis.

Why it matters

Potential benefit: If successful, this work could enable more personalized cardiac rehabilitation by predicting which patients will respond best to specific interventions, improving recovery and reducing future cardiac events.

How similar studies have gone: Previous research using remote monitoring and artificial intelligence to predict cardiac outcomes has shown promising but still exploratory results rather than definitive clinical adoption.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Coronary Artery Disease (CAD) patients after myocardial infarction (STEMI/NSTEMI) and/or angioplasty and/or Percutaneous Coronary Intervention (PCI) and/or coronary artery bypass graft surgery who participate in phase II Cardiac Rehabilitation (CR).

Exclusion Criteria:

* Incapability to give informed consent
* Conditions that prevent patients from participation in CR including unstable coronary or cerebrovascular conditions and acute infections

Where it's running

  • Klinik Königsfeld
    Ennepetal, North Rhine-Westphalia, Germany
    Recruiting

Study contacts

  • Principal investigator: Boris Schmitz, PhD — University of Witten/Herdecke, Dpt. Rehabilitation Sciences
  • Study coordinator: Boris Schmitz, PhD
  • Email: boris.schmitz@uni-wh.de
  • Phone: 004923339888156

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.